Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9298448 | 1.00 | GAA (0.51) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL2549625 | 1.00 | GAA (0.51) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL8515513 | 0.90 | SMN1; SMN2 (0.48) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL8515514 | 0.90 | SMN1; SMN2 (0.48) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL28561885 | 0.90 | CYP19A1 (0.54) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL9390312 | 0.87 | NPC1 (0.53) | SMN1; SMN2RAB9ANPC1TDP1MAPT | |
| SCHEMBL9390308 | 0.87 | NPC1 (0.53) | SMN1; SMN2RAB9ANPC1TDP1MAPT | |
| SCHEMBL8996036 | 0.87 | RAB9A (0.55) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL12891827 | 0.86 | NPC1 (0.59) | SMN1; SMN2RAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL8535569 | 0.85 | SMN1; SMN2 (0.49) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751163-A | 4-chloroquinoline compound and synthesis method thereof | 辽宁大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-107459475-B | Method for synthesizing pyrrole-4-ketone derivative by visible light catalysis | 中国科学院理化技术研究所 | 2019-09-27 | — | — | CN | disclosed |
| CN-107459475-A | Method for synthesizing pyrrole-4-ketone by visible light catalysis | 中国科学院理化技术研究所 | 2017-12-12 | — | — | CN | disclosed |
| US-8716485-B2 | Pyrazole synthesis by coupling of carboxylic acid derivatives and enamines | WESTFÄLISHE WILHELMS-UNIVERSITÄT MÜNSTER (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20130012715-A1 | PYRAZOLE SYNTHESIS BY COUPLING OF CARBOXYLIC ACID DERIVATIVES AND ENAMINES | WESTFAELISCHE WILHELMS UNIVERSITAET MUENSTER (DE) | 2013-01-10 | — | — | US | disclosed |
| EP-1687275-A4 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | AGT SCIENCE LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| EP-1687275-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | Merck & Co., Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051915-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-0550635-B1 | FUSED RING ANALOGS OF NITROGEN CONTAINING NONAROMATIC HETEROCYCLES | PFIZER (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5374656-A | Nervous system disorders, gastrointestinal disorders | RHONE-POULENC RORER, S.A. (FR) | 1994-12-20 | — | — | US | disclosed |
| EP-0550635-A1 | FUSED RING ANALOGS OF NITROGEN CONTAINING NONAROMATIC HETEROCYCLES. | PFIZER (US) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992006079-A1 | FUSED RING ANALOGS OF NITROGEN CONTAINING NONAROMATIC HETEROCYCLES | PFIZER INC. (US) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012715-A1 | PYRAZOLE SYNTHESIS BY COUPLING OF CARBOXYLIC ACID DERIVATIVES AND ENAMINES | PC, ENO1, PDK2 | GAA 1666/4885SMN1; SMN2 4182/4885RAB9A 2706/4885 |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | PER2, CNR2, OPRD1 | GAA 2422/4885SMN1; SMN2 2110/4885RAB9A 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.